Seaport Therapeutics, Inc. Common Stock

NASDAQ:SPTX

Biotechnology

Healthcare
$18.31 +0.58%

+$0.10 today

Market cap
$980.14M
Beta
0.00
52W Low $14.85High $23.00

Volume 0.68M

Average 0.41M

Returns on capital

Seaport Therapeutics, Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

No return metrics data available.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Daphne Zohar

Founder, CEO, President & DirectorUSD 1.26M551.09M2.04%

Antony Loebel

Chief Medical Officer & President of Clinical DevelopmentUSD 670.25K65——

Michael C. Chen

Co-Founder & Chief Scientific OfficerUSD 604.5K42——

Steven Paul

Founder & Non-Employee Chair of the BoardUSD 500K75——

Lana Gladstein

General Counsel—50——

Lauren A. White

Chief Financial Officer—47——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$335,093.00

Sells

0

$0.00

Net Transaction Value

+$335,093.00

Net buying

Most Active

Torres Denice

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 3, 26

Torres Denice

Direct

Buy$99.3K
Jun 22, 26

HOMBACH ROBERT J.

Indirect

Buy$235.8K

Summary

Insiders reported 2 buys worth $335,093.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $335,093.00. Torres Denice was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

No growth data available

Competitors

Who does Seaport Therapeutics, Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SPTX's management, answered from reported figures.

Who manages SPTX?

Seaport Therapeutics, Inc. Common Stock (SPTX) lists 6 active executives. The top listed executive is Antony Loebel, Chief Medical Officer & President of Clinical Development.

Are SPTX insiders buying or selling?

Recent insider activity shows net buying of $335,093.00.